




Wake Forest University School of Medicine



A Cancer Center Designated by the National Cancer Institute

WE WORK AS ONE



Ruben A. Mesa, MD, FACP

President, Enterprise Cancer Service Line Atrium Health Executive Director Atrium Health Wake Forest Baptist Comprehensive Cancer Center Enterprise Senior Vice President Atrium Health Vice Dean for Cancer Programs – Wake Forest School of Medicine Professor of Medicine Ruben.Mesa@Atriumhealth.org

Disclosures - Ruben Mesa, MD

- Consultant (Honoraria) over past 3 years
 - Novartis
 - Sierra Oncology
 - Genentech
 - Sierra
 - Blueprint
 - Geron
 - Telios
 - CTI
 - Incyte
 - BMS
 - Abbvie
 - GSK

- Research Support
 - Incyte
 - Sierra
 - CTI
 - BMS
 - Abbvie
 - Genentech
 - Blueprint
 - Morphosys

Gaps and Guidelines – MPNs 2023

Goals and Targets


- ET and PV
- JAK Inhibitors as Foundation
- Non JAKi MOA
- Other Gaps
- Putting it all Together






Assessing MPN Burden

WHO Diagnosis Does Not Tell Whole Story




What do symptoms tell us about MPN Biology?




Fatigue






Cancer, vol. 92, no. 6, pp. 1684-1688, 2001. Cancer, vol. 104, no. 4,pp. 788-793, 2005. Brain, Behavior, and Immunity, vol. 21,no. 3, pp. 251-258, 2007. Cancer, vol. 106, no. 4, pp. 751-758, 2006. [American Journal ofPsychiatry, vol. 158, no. 8, pp. 1252-1257, 2001.


Abdominal Symptoms



Constitutional Symptoms



Microvascular Symptoms



What is Precise and Personalized Cancer Care?

Molecular Features of Disease Communication Social DOH Health Literacy

Geography Employment Financial Pressures

Individual Cultural Value Factors In Treatment Planning?



Individualized Survivorship?

Individual Health Factors In Treatment Planning?

Individualized Supportive Care Needs?

> Disease impact Symptoms QoL?





Weaving Molecular Data into Cancer Care




Image: Nature 202 Atrium Health



Therapy of MPNs 2023


- Goals and Targets
- ET and PV
- JAK Inhibitors as Foundation
- Non JAKi MOA
- Other Gaps
- Putting it all Together





What is a treatment guideline?












Gap 4 Predicting Progression and what is adequate response?

NCCN NCCN NCCN Network[®]

nsive NCCN Guidelines Version 3.2022 Essential Thrombocythemia

TREATMENT FOR HIGH-RISK ESSENTIAL THROMBOCYTHEMIA^a



Gerds, AT et al. J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062.


🛩 @AaronGerds 🚹 Cleveland Clinic



Gap 4 Predicting Progression and what is adequate response?

NCCN NCCN Network®

NCCN Guidelines Version 3.2022 Polycythemia Vera



Gerds, AT et al. J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062.




Therapy of MPNs 2023


- Goals and Targets
- ET and PV
- JAK Inhibitors as Foundation
- Non JAKi MOA
- Other Gaps
- Putting it all Together





JAK Inhibitor Landscape 2023






Therapy of MPNs 2023

- Goals and Targets
- ET and PV
- JAK Inhibitors as Foundation
- Non JAKi MOA
- Other Gaps
- Putting it all Together






Current Phase III trials in MF



Immune Therapies



anti-CTLA-4 ipilimumab 2011 melanoma

anti-PD-1 pembrolizumab 2014 nivolumab 2014

melanoma, renal, lung Hodgkin's disease, head and neck, MSI+, DDR+ bladder, Merkel cell, ped's colorectal, hepatocellular

anti-PD-L1 atezolizumab 2017 avelumab 2017 durvalumab 2017 Merkel cell, bladder, lung





Target MF Stem Cell: NCI Funded MPN RC




Figure 1. Bench to bed strategy to deplete MF stem cells.





Table 1. Members of the MPN-RC	
Institutions	Members
Icahn School of Medicine at Mount Sinai, NY, NY*	Ronald Hoffman, MD (PI)
Cedars-Sinai Medical Center, Los Angeles, CA*	Ronald L. Paquette, MD*
Cleveland Clinic Lerner College of Medicine of	Aaron Gerds, MD*
CWRU, Cleveland, OH*	
Mayo Clinic Arizona, Scottsdale, AZ*	Amylou Dueck, PhD
Mays Cancer Center; University of Texas Health	Ruben Mesa, MD*
Science Center, San Antonio, TX*	
Moffitt Cancer Center, Tampa FL*	Andrew Kuykendall, MD*
St. Jude Children's Research Hospital, Inc.	John Crispino, PhD
Sloan Kettering Institute for Cancer Research, NY,	Ross Levine, MD
NY*	
University of Kansas Medical Center Research	Abdulraheem Yacoub, MD*
Institute, Westwood, KS*	
Wake Forest University Health Sciences, Winston-	Rupali Bhave*
Salem, NC*	
Roswell Park Comprehensive Cancer Center, Buffalo,	Eunice Wang, MD*
NY*	
Canada	
University Health Network, Toronto, Canada*	Vikas Gupta, MD*
* Denotes PI of Clinical Sites	





American Society of Hematology

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms

Edimara Reis¹, Rebecca Buonpane¹, Hamza Celik¹, Caroline Marty², Angela Lei¹, Fatoumata Jobe¹, Mark Rupar¹, Yue Zhang¹, Darlise DiMatteo¹, Rahel Awdew¹, William Vainchenker², Jing Zhou¹, Ian Hitchcock³, Isabelle Plo², Horacio Nastri¹, Patrick Mayes¹


¹Incyte Corporation, Wilmington, DE, USA; ²INSERM UMR 1287, Université Paris-Saclay, Gustave Roussy, Villejuif, France; ³York Biomedical Research Institute, Department of Biology, University of York, York, UK

FOR MEDICAL INFORMATION PURPOSES ONLY. NOT FOR PROMOTIONAL USE, DO NOT COPY, DISTRIBUTE OR OTHERWISE REPRODUCE.






Anti-mutCALR antibody selectivity inhibits oncogenic cell proliferation








INCA033989 selectively inhibits cell proliferation and induces death of mutCALR⁺ cells






FOR MEDICAL INFORMATION PURPOSES ONLY. NOT FOR PROMOTIONAL USE. DO NOT COPY, DISTRIBUTE OR OTHERWISE REPRODUC






Cellular Therapies




Tisagenlecleucel (KymriahTM) – ALL, DLBCL Axicabtagene ciloleucel (YescartaTM) - Lymphoma



Click to edit Master title style










Consumer-based meditation app, calm, for treatment of sleep disturbance in hematological cancer patients







Therapy of MPNs 2023

- Goals and Targets
- ET and PV
- JAK Inhibitors as Foundation
- Non JAKi MOA
- Other Gaps
- Putting it all Together





We lack effective early detection approaches to diagnose many types of cancer.

We have curative therapies that come at the cost of serious side effects.

We have too few methods to prevent cancer.

We leave too many patients and families to navigate the disease on their own.

Cancer as we know it today



We have stark inequities in diagnosis, treatment and trial access, and patient outcomes, based on race, region and resources.

Cancer kills 600,000 people per year in the United States, including close to 1,800 aged 19 and under.

We have limited success in some of the toughest to treat and rare cancers.





What it will take to end cancer as we know it

Build on 50 years of progress	Advance health equity	Personalize cancer care
Embrace technology and innovation to learn from every patient	Inspire the next generation of diverse researchers	Prepare for the challenges of the future





Reignition of the Cancer Moonshot 2022



7 Pillars – Progress for

- **1. Cancer Early Detection**
- 2. Prevention
- 3. Equity
- 4. Precision Medicine
- 5. Rare & Childhood Cancers
- 6. Supporting Patients &

Caregivers

7. Learning From Patients



Priority Actions

- Close the Screening Gap
- Understand & Address Environmental/Toxic Exposures
- Decrease Preventable Cancers
- Bring Cutting Edge Research Through Pipeline to Patients & Communities
- Support Patients and Caregivers





A Team Based Approach for Care

Helping Cancer Patients RISE Beyond Their Cancer!





CANCER MEDICAL SPECIALTIES

- Cardio-Oncology
- Onco-Nephrology
- Optho-Oncology
- Palliative Medicine
- Survivorship Clinics
- Endocrine
- Medical Management Clinic

PATIENT & CAREGIVER SERVICES

- Nutrition
- Genetic Counseling
- Psycho-Social Support
- Social Work
- Transportation
- Holistic Support Programs
- Financial Counseling





18:21 · 2/23/22 · <u>TweetDeck</u> 290 Retweets 25 Quote <u>Tweets</u>





trium Health

Standardizing MPN Data Collection

Pre MPN History

- Complete Demographics
- Co-morbidities
- Meds
- Fam Hx
- Prior Events/ Symptoms

MPN Presentation

- Labs/ Exam
- MPN SAF
- Marrow and NGS

MPN Course

- Meds/ Toxicities (inc \$)
- Events
- Serial Labs/ MPN SAF
- Repeat Marrow NGS

Outcomes

- Events
- Progression
- Co-Morbidities
- Mortality








Advancing Inclusive Research®

Enterprise-wide initiative focused on tackling disparities in clinical research



There are well-characterized disparities in clinical research real world patient populations is required to improve clinical outcomes for patients

realize the promise of personalized healthcare for all

Sources: https://www.census.gov/quickfacts/fact/table/US/PST045216; https://i0.wp.com/www.brookings.edu/wp-content/uploads/2018/03/20180910_metro_Frey_census-datacharts-revised-

Fig1.png?w=768&crop=0%2C0px%2C100%2C9999px&ssl=1, Nature 538, 161-164 (13 October 2016) doi:10.1038/538161a

https://statisticalatlas.com/state/California/Race-and-Ethnicity; US Census Bureau, specifically from the 2010 census, and from the 2012-2016 American Community Survey. Coakley M, Fadiran EO, Parrish LJ, Griffith RA, Weiss E, Carter C. J Womens Health (Larchmt). 2012;21(7):713-716.

Mills, M.C., Rahal, C. Nat Genet 52, 242-243 (2020).

https://www.appliedclinicaltrialsonline.com/view/special-populations-underrepresented-oncology-research-challenges-and-solutions-engage-hispanic-popu





What is inclusivity?

- 1)Race?
 2)Ethnicity?
 3)Gender?
- 4) Age span (across the lifespan)?
- 5)Sexual Orientation?
- 6)Basically a trial should reflect the population, not a subset





Cancer Focus: Testimony on Diversity for Clinical Trials Mays Cancer Center


117th US Congress: Energy & Commerce March 17, 2022







Advancing Inclusive Research







Why make a trial inclusive?

- 1) All patients should have a chance to benefit from the benefits of a trial (JUSTICE)
- 2) Inclusive trials help identify differences in efficacy between subgroups that might better lead to treatment planning (GOOD SCIENCE)
- 3) Inclusive trials might help to identify differences between subgroups in terms of toxicity that might lead to more precise dosing and use (GOOD PATIENT CARE)





Therapy of MPNs 2023

- Goals and Targets
- ET and PV
- JAK Inhibitors as Foundation
- Non JAKi MOA
- Other Gaps
- Putting it all Together





What is Precise and Personalized Cancer Care?

Molecular Features of Disease -Multi-Omic -Dx, treatment, survivorship

> Geography Employment Financial Pressures

Individual Cultural Value Factors In Treatment Planning? Communication Social DOH Health Literacy



Individualized Survivorship?

Individual Health Factors In Treatment Planning?

Individualized Supportive Care Needs?

> Disease impact Symptoms QoL?





MPN Patient Community

MPN Group	Focus	Website
MPN Research Foundation	RES-ED-ADV	www.Mpnresearchfoundation.org
Leukemia and Lymphoma Society*	RES-ED-ADV	www.lls.org
MPN Advocacy & Education International*	ED-ADV	www.mpnadvocacy.com
MPN Education Foundation*	ED-COMM	www.mpninfo.org
AAMDS Foundation	ED	www.aamds.org
MPN Voice	ED	www.mpnvoice.org.uk
MPN HUB*	ED	www.mpn-hub.com
MPN Advocates Network	ED-ADV	www.mpn-advocates.net
Global MPN Scientific Foundation*	RES-ED-ADV	www.gmpnsf.org
MPN Forum Facebook Group	ED-COMM	https://www.facebook.com/groups/ou rmpnforum/











Mays Cancer Center UT Health San Antonio MDAnderson Cancer Center





















OUT He





